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Body silhouette trajectories 
over the Lifespan and Insomnia 
symptoms: the paris prospective 
Study 3
Q. Lisan  1,2,3, M. Tafflet1,2, F. thomas4, P. Boutouyrie1,2,5, C. Guibout1,2, J. Haba-Rubio6, 
R. Climie1,2,7, M. C. périer1,2, T. Van sloten1,2,8,9, B. pannier4, P. Marques-Vidal  6,10, 
X. Jouven1,2,11 & J. P. empana1,2
Insomnia symptoms are highly prevalent and associated with several adverse medical conditions, 
but only few determinants, including non-modifiable ones, have been highlighted. We investigated 
associations between body silhouette trajectories over the lifespan and insomnia symptoms in 
adulthood. From a community-based study, 7 496 men and women aged 50–75 years recalled their body 
silhouette at age 8, 15, 25, 35 and 45, and rated the frequency of insomnia symptoms on a standardized 
sleep questionnaire. An Epworth Sleepiness Scale ≥11 defined excessive daytime sleepiness (EDS). 
Using a group-based trajectory modeling, we identified five body silhouette trajectories: a ‘lean-stable’ 
(32.7%), a ‘heavy-stable’ (8.1%), a ‘moderate-stable’ (32.5%), a ‘lean-increase’ (11%) and a ‘lean-marked 
increase’ (15.7%) trajectory. In multivariate logistic regression, compared to the ‘lean-stable’ trajectory, 
the ‘lean-marked increase’ and ‘heavy-stable’ trajectories were associated with a significant increased 
odd of having ≥1 insomnia symptoms as compared to none and of having a proxy for insomnia disorder 
(≥1 insomnia symptom and EDS). The association with the ‘lean-marked increase' trajectory’ was 
independent from body mass index measured at study recruitment. In conclusion, increasing body 
silhouette over the lifespan is associated with insomnia symptoms in adulthood, emphasizing the 
importance of weight gain prevention during the entire lifespan.
Insomnia symptoms such as difficulty in initiating or maintaining sleep, or early morning awakening, are the 
most common sleep complaints1,2 and are reported in up to 50% in adults3–5. The prevalence of insomnia symp-
toms is expected to rise, due to societal factors (24 h/7 days modern societies) and to changes in occupational 
factors such as increased work stress and shiftwork, and reduced time spent asleep6–8. Insomnia symptoms have 
been associated with an increased risk of hypertension, heart failure, coronary heart disease and mortality9–11. 
Moreover, insomnia symptoms are associated with multiple impairments in daily living – commonly referred to 
as insomnia disorder3,12 – such as home and work accident13, absenteeism and decreased work productivity, and 
impaired quality of life2,14,15.
Given these important social and medical consequences, prevention of insomnia symptoms represents a 
public health challenge. This is even more important as the affordability and efficacy of proposed treatments, 
including cognitive behavioral therapy and pharmacologic treatments, have not been firmly established16,17. A 
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better understanding of the risk factors for insomnia symptoms is a pre requisite to develop preventive strategies 
of insomnia symptoms. So far, few determinants of insomnia symptoms have been reported, including among 
others aging, female gender, lower socioeconomic status, shift work or depression3,5,18–22.
While increased adiposity – an epidemic and modifiable risk factor – has been associated with sleep disorders 
such as excessive daytime sleepiness23,24 or obstructive sleep apnea25, inconsistent and contradictory associations 
have been reported with insomnia symptoms21,26,27. This discrepancy may partly rely on the cross-sectional design 
of most studies21,26,27, or the limited number of repeated measures of adiposity over time among longitudinal 
studies28,29. Indeed, adiposity changes over time, especially at critical periods such as during puberty and men-
opause. Hence, repeated measures of adiposity over a long time period within the same individual may provide 
more accurate information regarding its evolution and its potential association with insomnia symptoms. In large 
epidemiological studies, repeated assessments of objective measures of adiposity are rarely available, in particu-
lar regarding childhood and adolescent periods. Under these circumstances, self-reported body silhouettes at 
different ages may represent a simple and reliable alternative30,31. By combining recall of body shapes at different 
ages within the same subject, it is possible to construct body silhouette trajectories. This is of public health impor-
tance since body silhouette trajectories have been recently associated with incident type 2 diabetes, cancer and 
mortality32–35.
Therefore, in this study, we sought to investigate the potential associations between body silhouette trajecto-
ries over the lifespan from childhood to adulthood and insomnia symptoms in adulthood.
Results
Characteristics of the study population. The study population comprised 61.5% of men and the median 
age was 59.2 years (interquartile range 54.5–63.6 years). Overall, 61.4% reported at least one insomnia symptom 
and 11.7% reported insomnia disorder (proxy). Furthermore, 55.1% of the participants had DMS, 26.5% EMA 
and 18% DIS.
Among the five body silhouette trajectories (Fig. 1), 8.1% of the participants had a ‘heavy-stable’ trajectory, 
32.5% a ‘moderate-stable’ and 32.7% a ‘lean-stable’; 11% had a ‘lean-increase’ trajectory and 15.7% a ‘lean-marked 
increase’ trajectory.
The main characteristics of the study population according to the body silhouettes trajectories are reported 
in Table 1. In particular, the presence of at least one insomnia symptom and the presence of insomnia disor-
der (proxy) were more frequently observed among participants belonging to the ‘lean-marked increase’ and 
‘heavy-stable’ trajectories.
Associations of body silhouette trajectories with insomnia symptoms and insomnia disorder. 
The unadjusted and multivariable adjusted ORs of body silhouettes trajectories for the presence of at least one 
insomnia symptom and for the presence of insomnia disorder (proxy) are presented in Table 2 (OR of the covari-
ates are shown in Table S1). In multivariate analysis and compared to the ‘lean-stable’ trajectory, the ‘lean-marked 
increase’ trajectory was associated with the presence of at least one insomnia symptom (OR = 1.36; 95% CI 1.15–
1.61) and with the presence of insomnia disorder (OR = 1.67; 95% CI 1.32–2.12). Similarly, the ‘heavy-stable’ tra-
jectory was associated with both ≥1 insomnia symptom (OR 1.28, 95% CI 1.03–1.58) and the proxy for insomnia 
disorder (OR 1.50, 95% CI 1.12–2.01).
The results of the sex-stratified analysis are reported in Table S2. In both men and women, the ‘lean-marked 
increased’ trajectory was significantly associated with the presence of at least one insomnia symptom, and with 
the presence of insomnia disorder (proxy). The effect size of the association with at least one insomnia symptom 
was stronger in women compared to men. The ‘heavy stable’ trajectory was significantly associated with the pres-
ence of at least one insomnia symptom in women, and with the presence of insomnia disorder (proxy) in men.
The results of the analysis between body silhouette trajectories and each insomnia symptom are presented in 
Table S3. Statistically significant associations were found for the ‘lean-marked increased’ trajectory with DMS and 
EMA, and with the ‘lean increased’ trajectory with DIS.


























Figure 1. Trajectories of body silhouette. Note: percentages represent the proportion of the population in each 
trajectory.
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supplementary analyses. As presented in the Table S4, when considering body silhouette at age 45, only 
silhouettes E and G (indicating high level of adiposity) were associated with ≥1 insomnia symptom and with 
proxy for insomnia disorder.
Associations of the ‘lean-marked increase’ trajectory with ≥1 insomnia symptom (OR 1.33, 95% CI 1.12–1.58) 
and with the proxy for insomnia disorder (OR 1.55, 95% CI 1.22–1.97) remained unchanged after adjusting for 
a proxy for SDB.
When considering the score of insomnia symptoms, the ‘lean-increase’, ‘lean-marked increase’ and 
‘heavy-stable’ trajectories were all associated with a higher score of insomnia symptoms (Table S5).
Compared to a BMI between 18.5 and 25 kg/m2 at study recruitment, a BMI > 30 kg/m2 was significantly 
associated with the proxy for insomnia disorder (OR 1.68, 95% CI 1.29–2.17) but not with the presence of at least 
one insomnia symptom (OR 1.17, 95% CI 0.96–1.43) in multivariate analysis. Neither overweight (BMI from 25 
to 29.9 kg/m2) nor underweight (BMI < 18.5 kg/m2) was related to any insomnia outcome.
Body silhouette trajectory
Lean-stable 




increase N = 1 176
Moderate-stable 
N = 2 449
Heavy-stable 
N = 610
Insomnia symptoms and proxy for insomnia disorder
  At least one insomnia symptom 1 445 (59.3) 512 (62.2) 750 (63.8) 1 494 (61.0) 405 (66.4)
  Insomnia disorder (proxy) 241 (9.9) 92 (11.2) 175 (14.9) 271 (11.1) 98 (16.1)
Socio-demographics data
  Male gender 1 515 (62.1) 588 (71.4) 879 (74.7) 1 343 (54.8) 285 (46.7)
  Age (years) 59.7 ± 6.07 60.5 ± 6.32 59.3 ± 6.27 59.5 ± 6.30 59.0 ± 6.07
  Body mass index (kg/m2) 23.7 ± 2.95 24.0 ± 3.11 26.8 ± 3.47 25.2 ± 3.46 27.8 ± 4.36
Birth weight categories*
  <2.5 kg 111 (5.3) 61 (9.4) 68 (7.1) 83 (4.0) 20 (3.9)
  2.5–4 kg 1 805 (86.9) 542 (83.8) 803 (84.1) 1 775 (85.4) 411 (80.4)
  >4 kg 161 (7.8) 44 (6.8) 84 (8.8) 220 (10.6) 80 (15.7)
Education level
  No graduation 63 (2.61) 33 (4.06) 70 (5.99) 70 (2.88) 19 (3.14)
  Under high school diploma 498 (20.7) 189 (23.2) 310 (26.5) 528 (21.7) 167 (27.6)
  ≥high school diploma 1 849 (76.7) 591 (72.7) 789 (67.5) 1 833 (75.4) 420 (69.3)
  Current smoker 312 (12.8) 106 (12.9) 145 (12.4) 358 (14.6) 102 (16.8)
Coffee consumption
  Never 426 (17.6) 160 (19.6) 165 (14.2) 364 (15.0) 81 (13.4)
  1–4 cups a day 1 842 (76.0) 598 (73.1) 898 (77.1) 1 865 (76.7) 458 (75.6)
  ≥5 cups a day 157 (6.47) 60 (7.33) 101 (8.68) 204 (8.38) 67 (11.1)
  Living alone 588 (24.3) 189 (23.0) 251 (21.4) 616 (25.3) 173 (28.5)
Alcohol consumption
   Never 237 (9.90) 79 (9.77) 122 (10.5) 256 (10.6) 68 (11.3)
  1–2 drinks per day 1 855 (77.5) 610 (75.4) 849 (73.1) 1 871 (77.5) 484 (80.1)
  ≥3 drinks per day 302 (12.6) 120 (14.8) 191 (16.4) 287 (11.9) 52 (8.61)
  Score of physical activity 6.26 ± 1.41 6.17 ± 1.43 6.19 ± 1.41 6.24 ± 1.42 6.26 ± 1.53
Comorbid conditions
  Depression 168 (6.94) 61 (7.43) 105 (8.94) 207 (8.48) 77 (12.7)
  Stress (PSS4 score) 3.62 ± 2.70 3.70 ± 2.76 3.82 ± 2.69 3.75 ± 2.71 4.16 ± 2.93
  Prevalent CVD 33 (1.36) 20 (2.44) 32 (2.73) 49 (2.01) 10 (1.64)
  Hypertension 694 (28.6) 296 (36.3) 469 (40.0) 839 (34.5) 227 (37.4)
  Diabetes 46 (1.89) 33 (4.01) 77 (6.58) 77 (3.16) 21 (3.47)
Sleep related variables
  Excessive daytime sleepiness 363 (14.9) 129 (15.7) 230 (19.6) 382 (15.7) 120 (19.7)
  Night working 37 (1.52) 17 (2.07) 21 (1.79) 30 (1.23) 8 (1.31)
  SDB (proxy) 26 (1.07) 12 (1.47) 105 (8.98) 97 (3.99) 89 (14.8)
  Use of sleep related medications 77 (4.14) 30 (4.72) 52 (5.45) 87 (4.51) 25 (4.80)
Sleep duration (hours)
  6–9 h per night 2 047 (87.0) 664 (84.9) 948 (83.3) 2 037 (86.4) 494 (85.5)
  <6 h per night 277 (11.8) 106 (13.6) 173 (15.2) 290 (12.3) 80 (13.8)
  >9 h per night 29 (1.23) 12 (1.53) 17 (1.49) 31 (1.31) 4 (0.69)
Table 1. Study participants’ characteristics according to the body silhouette trajectory. Abbreviations: CVD: 
cardiovascular disease, SDB: sleep disordered breathing. Note: values are number of participants (percentages) 
or mean ± standard deviation. *Available in n = 6268 subjects.
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After adjusting the analysis of body silhouette trajectories for BMI at study recruitment, the ‘heavy-stable’ 
trajectory was significantly associated with ≥1 insomnia symptom and was no longer associated with insomnia 
disorder (proxy). Associations of the ‘lean-marked increase’ trajectory with ≥1 insomnia symptom and with 
insomnia disorder (proxy) remained significant. In this analysis, only BMI > 30 kg/m2 as compared to BMI from 
18.5 to 25 kg/m2 was associated with the proxy for insomnia disorder (OR 1.49, 95% CI 1.12–1.95) but not for the 
presence of at least one insomnia symptom (Table S6).
Birth weight was available in 6 268 participants of the analytic sample. Additional adjustment for birth weight 
categories did not affect the associations of body silhouette trajectories with insomnia outcomes, and in this 
model, birth weigh categories < 2.5 kg or above 4 kg as compared to 2.4–4 kg were not related to any insomnia 
outcomes (not shown).
Similarly, further adjustment for type 2 diabetes did not affect associations of body silhouette trajectories with 
insomnia outcomes (not shown).
Discussion
Using a lifetime approach of self-reported body silhouettes from childhood (8 years of age) to adulthood (45 
years) in 7 496 community-dwelling men and women, we first identified five body silhouettes trajectories includ-
ing ‘heavy-stable’, ‘moderate-stable’ and ‘lean-stable’; and a ‘lean increase’ and ‘lean-marked increase’ trajectory 
group. Second, we found that participants with a ‘lean-marked increase’ trajectory, and to a lesser extent those 
with a ‘heavy-stable’ trajectory, had a significant increased odds of having insomnia symptoms and insomnia dis-
order (proxy) in adulthood compared to those with a ‘lean-stable’ trajectory. These associations were independent 
of major confounding factors.
In cross-sectional studies, in one study the increased odds of insomnia symptoms associated with obesity 
(BMI ≥ 30 kg/m2) disappeared after adjustment for confounders such as depression21, while in another, obesity 
was related to lower odds of insomnia symptoms in women but not in men27.
Regarding the few existing prospective studies, in the Penn State Sleep Cohort obesity at baseline showed 
a marginally significant 47% increased odds of incident chronic insomnia over a 7.5-year follow-up after con-
trolling for sociodemographic and behavioral factors, but this association attenuated and was no longer signifi-
cant in fully-adjusted analysis including comorbidities36. In the Helsinki Health Study, higher BMI in women was 
associated with persistent (occasional and frequent) insomnia symptoms, and with incident and an increase in 
insomnia symptoms over two examinations26. Similar associations were found in men but in general with weaker 
effect size. There were however some counterintuitive findings in that study such that obese and severely obese 
were more likely to report full or partial remission of insomnia symptoms, whereas men with a BMI between 30 
and 34.99 kg/m2 were less likely to report persistent occasional insomnia symptoms compared to normo weighted 
men. However, these latter findings were based on small groups and require replication, as acknowledged by the 
authors26.
Studies investigating changes in BMI with the risk of insomnia symptoms are even scarcer. In one study con-
ducted exclusively in men (n = 2 602), change in BMI over 10 years was neither associated with persistent or 
incident insomnia symptoms nor with remission of insomnia symptoms, contrary to higher baseline BMI28. In a 
smaller study (n = 464) exploring the psychosocial and biological determinants of change in sleep quality assessed 
three times over 1 year, subjects with incident insomnia symptoms and with incident insomnia syndrome had 
moderate increase in BMI over the study period29.
We extended the results of prior studies in several aspects. First, our study population is three to four times 
larger than previous studies and considered both men and women. Second, while previous studies considered 
up to two measures of adiposity per study participant over time, we used for the first time a lifetime approach 
considering between three to five body silhouettes estimations from childhood to adulthood per participant. 
Self-reported body silhouettes represent reliable markers of adiposity in the absence of objective measures30,31. 
Accordingly, correlation coefficients from 0.53 to 0.75 have been reported between the recall of body silhou-
ette at different ages (between 5 and 20-year old) and objective measures of BMI at the corresponding ages30. 
Consistently, in the present study, the Pearson correlation coefficient between body silhouettes at age 45 and 
objectively measured BMI at age 50 was 0.60. On the other hand, body silhouettes also integrate body image 
Outcome
≥1 symptom versus 0
Proxy for insomnia disorder (≥1 
symptom and EDS)
Unadjusted Fully adjusted Unadjusted Fully adjusted
Body silhouette trajectory
  Lean-stable 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  Lean-increase 1.13 (0.96–1.33) 1.17 (0.97–1.42) 1.15 (0.89–1.47) 1.10 (0.81–1.48)
  Lean-marked increase 1.21 (1.05–1.40) 1.36 (1.15–1.61) 1.60 (1.29–1.96) 1.67 (1.32–2.12)
  Moderate-stable 1.08 (0.96–1.21) 1.09 (0.95–1.25) 1.14 (0.95–1.36) 1.08 (0.88–1.34)
  Heavy-stable 1.36 (1.13–1.64) 1.28 (1.03–1.58) 1.75 (1.35–2.24) 1.50 (1.12–2.01)
Table 2. Multivariate associations of body silhouette trajectories for insomnia symptoms and for insomnia 
disorder (proxy). Abbreviations: OR: odd ratio, CI: confidence interval. Note: fully adjusted models are adjusted 
for age, sex, education level, coffee and alcohol consumptions, living alone, physical activity, depression, stress 
and sleep medications.
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perception and may thus bring information beyond adiposity itself. Interestingly, the associations of insomnia 
symptoms with body silhouette trajectories were independent from BMI. Thus, body silhouette trajectories may 
potentially add information beyond BMI regarding the likelihood of insomnia symptoms.
The observed associations between body silhouettes trajectories and insomnia outcomes were independent of 
major confounding variables such as psychological factors. This is of primary importance as strong associations 
have been highlighted between depression, anxiety and insomnia symptoms21,22,37. Taking these psychological 
factors into account is also important as they may influence body image perception and thus the self-reported 
body silhouette. Indeed, in our study depression and stress were associated with insomnia symptoms and insom-
nia syndrome disorder (proxy) together with body silhouettes trajectories. Furthermore, the observed associa-
tions with the body silhouette trajectories could reflect associations with BMI at study recruitment on one hand, 
and/or with the last body silhouette at age 45 on the other hand. However, the results of sensitivity analyses do not 
support these hypotheses. Finally, consistent results were observed when alternative methods for defining body 
silhouettes trajectories and for calculating the burden of insomnia symptoms (insomnia symptoms score) were 
used. Taken together, these aspects support the robustness of the reported associations between body silhouettes 
trajectories and insomnia outcomes.
Although the pathophysiology of insomnia remains to be established38, some mechanisms may contribute to 
the association between body silhouettes trajectories and insomnia symptoms. For example, increased adiposity 
over the lifespan could result in over-activity of the hypothalamus-pituitary-adrenal axis and elevated cortisol 
level, possibly leading to symptoms of insomnia39,40. Likewise, the ‘lean-marked increase’ and ‘heavy-stable’ tra-
jectories of body silhouettes may be associated with an underlying chronic inflammation that contributes to 
insomnia symptoms onset38. Furthermore, body silhouettes trajectories may be the results of long-term exposure 
to behavioral and psychological processes that could explain part of the observed associations, although our anal-
ysis was independent of physical activity, depression and stress. In addition, diabetes might be on the path of the 
association between body silhouette trajectories and insomnia since body silhouette trajectories have been related 
to incident diabetes and diabetes is known to be associated with insomnia34,41. However, the sensitivity analysis 
did not support this. Last, epigenetics mechanisms might be involved as suggested by preliminary analyses of 
the methylation status of the circadian genes42. However, additional studies are required and the interplay with 
trajectories of adiposity to be demonstrated.
This study has clinical implications. Self-reported body silhouette is a simple tool that can be easily used 
in clinical practice, and our findings suggest that it may help to identify subjects at increased odds of develop-
ing insomnia symptoms. Weight gain prevention or weight reduction programs could be suggested to subjects 
presenting with an increasing body silhouette over the lifespan or with a consistently high body silhouette. If 
replicated, our results are of particular interest for subjects presenting with a marked increased body silhouette 
during early childhood. It offers the possibility to identify early in life those subjects who are at risk of having 
insomnia and propose to them adequate interventions to stop weight gain. As recently emphasized in a large 
population-based study including more than 50,000 children from birth to young adulthood, surveillance for 
BMI acceleration in childhood is of primary importance, even in the absence of obesity, since this acceleration is 
directly correlated to later obesity43.
We acknowledge the following limitations. First, body silhouettes were assessed retrospectively at study 
recruitment. This raises the issue of reverse causation, i.e. participants with insomnia symptoms may have been 
more likely to report at risk body silhouettes at each age. However, the trajectories identified in our study are 
very similar to the trajectories obtained in studies investigating mortality, cancer or type 2 diabetes32,33, mak-
ing this issue of reverse causation unlikely. Furthermore, the retrospective report of body silhouettes may yield 
misclassification; in addition, it is well known that obese people tend to underestimate their body silhouette 
while it is the opposite for underweighted people. As a result, this may attenuate the current association between 
body silhouettes trajectories and insomnia. Also, information on sleep since childhood would have been useful, 
but this was not available. Moreover, we cannot rule out that subjects reporting insomnia symptoms tend to 
systematically report one type of body silhouette more than another. However, the distribution of covariates 
according to the presence of insomnia symptoms or insomnia disorder (proxy) was in line with previous studies 
(results not shown), minimizing the possibility of this classification bias. Second, similar to most epidemiological 
studies22,29,36, we accounted for insomnia symptoms and not insomnia disorder as defined by the International 
Classification of Sleep Disorders44. However, we constructed a proxy for insomnia disorder, taking into account 
EDS. Third, in the absence of polysomnographic measurements, residual confounding by objectively diagnosed 
other sleep disorders such as SDB cannot be excluded, although we adjusted our analysis on a proxy for SDB. 
Fourth, the last body silhouette refers to age 45 while age at study recruitment ranged from 50 to 75 years. Thus, 
we may not have depicted complete body silhouettes trajectories, at least for the oldest participants. Last, the vast 
majority of the participants are of Caucasian origin; therefore, the generalizability of the results to more ethnically 
diverse populations needs to be evaluated.
In conclusion, marked increased body silhouette trajectory from childhood to adulthood together with a 
persistent heavy body silhouette were associated with a higher likelihood of having insomnia symptoms and 
insomnia disorder (proxy). Self-reported body silhouettes at different ages may represent an easy tool for subjects 
from the community and physicians to evaluate the risk of insomnia symptoms, and in turn to stimulate behav-
ioral change.
Material and Methods
study population. The design and main objectives of the Paris Prospective Study III (PPS3) have been pre-
viously published45. The PPS3 is an ongoing prospective observational cohort study on novel markers for the main 
phenotypes of cardiovascular diseases in mostly healthy subjects. Our study was registered in the World Health 
Organization international clinical trial registry platform (NCT00741728) and complies with the Declaration 
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of Helsinki. The Ethics Committee of the Cochin Hospital (Paris, France) approved the study protocol and all 
volunteers signed an informed consent form. Overall, 10 157 men and women aged 50–75 years were recruited 
at a large preventive medical center, the Centre d’Investigations Préventives et Cliniques (IPC), in Paris (France), 
between June, 2008 and June, 2012. The IPC is subsidized by the French National Insurance System for Salaried 
Workers (CNAMTS) and is one of the largest preventive medical centers in France, carrying out 20 to 25 000 free 
medical examinations per year to all working and retired employees and their families. The standard medical 
examination included a complete clinical examination including measurement of height, weight and blood pres-
sure, coupled with standard biological tests after an overnight fast. A self-administered questionnaire provided 
information related to professional activity, lifestyle (tobacco and alcohol consumption, physical activity, diet), 
personal and family medical history, current health status, and use of medications.
Body silhouettes. We used body silhouettes adapted from Stunkard46. Participants were asked to choose one 
body silhouette among seven proposed, that best depicted their body silhouette at ages 8, 15, 25, 35 and 45 years. 
Body silhouettes were presented using children and adult silhouettes, separately for men and women.
Insomnia symptoms. In a standardized questionnaire, participants self-rated as ‘never’, ‘rarely’, ‘regularly’ 
or ‘often’ the frequency with which they had 1) difficulties in initiating sleep (DIS), 2) difficulties in maintaining 
sleep (DMS) and 3) early morning awakening (EMA). These three symptoms are the most common symptoms 
of insomnia and have been used in several large epidemiologic studies4,19,21,27,37,47. Each insomnia symptom was 
defined as present if rated as ‘regularly’ or ‘often’. We also calculated a score for insomnia symptoms for each 
participant by summing the weight (i.e. from 0 for ‘never’ to 3 for ‘often’) of self-rated frequency of each insom-
nia symptom, resulting in a score ranging from 0 to 9 (higher score indicating higher number and frequency of 
insomnia symptoms).
other sleep related variables. Excessive daytime sleepiness. Participants were also asked to fill the Epworth 
Sleepiness Scale (ESS) to assess excessive daytime sleepiness (EDS). The ESS is a self-administered questionnaire 
containing eight questions evaluating the probability of dozing during daily activities, each question being rated 
from 0 (would never doze) to 3 (high chance of dozing). The ESS score is the sum of the eight items, ranging from 0 
to 2448. In accordance with the literature, we considered an ESS score of 11 and above to define EDS49–54.
Proxy for sleep-disordered breathing. In the absence of an objective measure of sleep disorder breathing (SDB), 
we used a proxy based on the self-rated frequency of snoring and the level of measured body mass index (BMI)55. 
Snoring rated as regular or often combined with a BMI ≥ 30 kg/m2 defined the presence of a possible SDB.
Working schedules and sleep related medications. Information on usual working schedules was recorded 
(i.e. working during the day or night). A medical doctor from the IPC checked current medication during a 
face-to-face interview with the study participants. To reduce under reporting, participants were asked to come to 
the IPC with either their most recent medical prescriptions and/or their medication packages. The World Health 
Organization Anatomical Therapeutic Chemical (ATC) classification was used to categorize medications; in par-
ticular sleep-related medications (i.e. those that influence sleep) were identified by ATC code N05 (psycholeptics).
outcomes. There were two outcomes. The first considered the presence of at least one insomnia symptom 
(versus no insomnia symptom). The second considered a proxy of insomnia disorder44, which combined the 
presence of at least one insomnia symptom together with the presence of EDS (to consider possible consequence 
of insomnia symptoms on daytime activity) (versus the absence of both insomnia symptom and EDS).
Covariates. Education level was considered as a categorical variable with three categories: 1) did not grad-
uate, 2) less than a high school diploma or, 3) high school diploma and above. Alcohol consumption was cate-
gorized as: never, one or two drinks a day and three or more drinks a day. Coffee consumption was categorized 
as: never, one to four cups a day and five or more cups a day. Depression score was assessed using the 13-items 
Questionnaire of Depression second version, Abridged (QD2A)56. The presence of depressive symptoms was 
defined by a QD2A score ≥ 7. Stress was estimated using the short version of the Perceived Stress Scale (PSS-4 
items)57. Prevalence of cardiovascular disease (CVD), including history of stroke, myocardial infarction or angina 
pectoris, was self-reported. Diabetes was defined by taking blood glucose lowing medication or fasting blood 
glucose > 7 mmol/L. Hypertension was defined by taking blood pressure lowering medication or systolic blood 
pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg. We used the validated Baecke score to evaluate 
physical activity at work, during recreational activities and during sport, a higher score indicating higher level of 
physical activity58. Birth weight was self-reported by the participant on the general health questionnaire in fixed 
categories including < 2.5 kg, 2.5–4 kg and >4 kg.
Analytic sample. Among the 10 157 participants included in PPS3, 8 583 participants completed the sleep 
questionnaires. Subjects with missing data on outcomes (n = 305), exposure (body silhouette trajectory, n = 735) 
or both (n = 47) were excluded. Hence, 7 496 participants were subsequently included for both main and sensitiv-
ity analyses. Comparisons between the included and excluded populations are reported in Table S7.
statistical analyses. To construct body silhouette trajectories, we selected subjects reporting their body sil-
houettes at a minimum at three ages of the five, including the earliest and the latest age, i.e. body silhouettes at age 
8 and 45 respectively. We used a group-based trajectory modeling implemented by SAS Proc Traj59,60. The optimal 
number of groups was identified from the change in the Bayesian Information Criterion (BIC) and the average 
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posterior probability (see below). The model including five trajectories presented the best BIC when compared 
with models including less than 5 trajectories. Furthermore, models including more than 5 trajectories had some 
average posterior probabilities <20%. Hence, the best model included five clusters of body silhouette trajectories 
and we named them after their visual aspect (‘lean-stable’, ‘lean-increase’, ‘lean-marked increase’, ‘moderate-stable’ 
and ‘heavy-stable’, Fig. 1). We then calculated the posterior probability for each participant to belong to one of the 
five trajectories and attributed each participant to a trajectory according to the highest probability among the five 
calculated. The average posterior probabilities for each trajectory were 86%, 88%, 79%, 89% and 91%, indicating 
very good allocation of subjects to the trajectories.
To test the reliability of the obtained trajectories, we also modeled trajectories using a different approach. We 
used a package implemented in R software (kml package) based on an implementation of k-means clustering 
algorithm adapted for longitudinal data61. According to quality criteria (Calinski & Harabasz, Ray & Turi and 
Davies & Bouldin), the optimal number of trajectories was five. Using this approach, we found very similar body 
silhouette trajectories as the ones previously described above (Fig. S1).
Logistic regression was used to quantify the relationship between body silhouette trajectory (using the 
‘lean-stable’ trajectory as the reference exposure category) and a) the presence of at least one insomnia symp-
tom (versus 0), and b) the proxy for insomnia disorder (versus no proxy for insomnia disorder). Results were 
expressed as odds ratio (OR) and 95% confidence intervals (CI). Unadjusted and adjusted ORs are provided. 
Regression models were adjusted for potential confounding factors such as age, sex, coffee and alcohol con-
sumption, education level, physical activity, living alone status, depression, stress and sleep related medications. 
Considering that there are gender differences in the prevalence of insomnia, we then conducted the previous 
analyses separately in men and women.
Several supplementary analyses were conducted. First, we investigated the associations between the last body 
silhouette (at age 45) and insomnia symptoms and insomnia disorder (proxy) and made qualitative comparisons 
with associations observed with body silhouette trajectories. Second, we adjusted the regression models for a 
proxy for SDB as defined previously. Third, we quantified the association between body silhouette trajectories 
and the score of insomnia symptoms as defined previously using linear regression analysis. Fourth, to assess to 
which extent body silhouette trajectories provide information beyond BMI, we further adjusted our analysis for 
BMI at study recruitment. Fifth, because birth weight may influence body shape trajectories, we further adjusted 
our analysis on birth weight. Sixth, because type 2 diabetes might be on the path of the association between body 
silhouette trajectories and insomnia34,41, we further adjusted the analysis on type 2 diabetes.
All analyses were two-sided and we considered a p-value < 0.05 as statistically significant. Statistical analyses 
were performed with R version 3.1.3 (www.r-project.org) and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Data Availability Statement
Data may be available on request to the last author.
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